Safety monitoring in bevacizumab (Avastin) treatment: Retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients

International Ophthalmology

Volumn 28, Issue 2, 2008, Pages 101-109

  Ziemssen, Focke ^a,b   Lüke, Matthias ^a   Messias, Andre ^a   Beutel, Julia ^a   Tatar, Olcay ^a   Zrenner, Eberhart ^a   Bartz Schmidt, Karl U ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Age related macular degeneration; Anti VEGF; Avastin; Bevacizumab; Panel D15; Toxicity

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; COLOR VISION; DRUG EFFECT; ELECTROOCULOGRAPHY; ELECTRORETINOGRAPHY; FEMALE; HUMAN; IMMUNOLOGY; INJECTION; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RETINA; RETINA MACULA DEGENERATION; VISUAL FIELD; VITREOUS BODY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COLOR PERCEPTION; ELECTROOCULOGRAPHY; ELECTRORETINOGRAPHY; FEMALE; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL FIELDS; VITREOUS BODY;

EID: 47749112506     PISSN: 01655701     EISSN: 15732630     Source Type: Journal    
DOI: 10.1007/s10792-007-9122-1     Document Type: Article

References (33)

1. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irnotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335- 2342. (Pubitemid 38702844)
2. Lazic R, Gabric N (2007) Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245:68-73. (Pubitemid 46766732)
3. Jorge R, Costa RA, Calucci D, Scott IU (2007) Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal teleangiectasis. Graefes Arch Clin Exp Ophthalmol. E-Pub.
4. Michels S (2006) Is intravitreal bevacizumab (Avastin) safe? Br J Ophthalmol 90:1333-1334. (Pubitemid 44702048)
5. Fung AE, Rosenfeld PJ, Reichel E (2006) The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90:1344-1349. (Pubitemid 44702055)
6. Lazarovici P, Marcinkiewicz C, Lelkes PI (2006) Cross talk between the cardiovascular and nervous system: neurotrophic effects of vascular endothelial growth factor (VEGF) and angiogenic effects of nerve growth factor (NGF). Curr Pharm Des 12:2609-2622.
7. Wang Y, Galvan V, Gorostiza O, Ataie M, Jin K, Greenberg DA (2006) Vascular endothelial growth factor improves recovery of sensimotoric and cognitive deficits after focal cerebral ischemia in rat. Brain Res 18:186-193. (Pubitemid 44436094)
8. Lanthony P (1986) Evaluation du Panel D15 désaturé. J Fr Ophthalmol 12:853-847.
9. Vingrys AJ, King-Smith PEA (1988) A quantitative scoring technique for panel tests of color vision. Inv Ophthalmol Vis Sci 29:50-63. (Pubitemid 18038771)
10. McCulley TJ, Golnik KC, Lam BL, Feuer WJ (2006) The effect of decreased visual acuity on clinical color vision testing. Am J Ophthalmol 141:194-196. (Pubitemid 43016196)
11. Brown M, Marmor M, Vaegan, Zrenner E, Brigell M, Bach M (2006) ISCEV standard for clinical electro-oculography (EOG) 2006. Doc Ophthalmol 113:205-212. (Pubitemid 44835005)
12. Naka KI, Rushton WAH (1966) S-potentials from colour units in the retina of the fish (cyprinidae). J Physiol 185:536-555.
13. Langellan N, Wouters B, Moll AC, de Boer MR, van Rens GHMB (2005) Intra- and interrater agreement and reliability of the functional field score. Ophthalmic Physiol Opt 25:136-142. (Pubitemid 41702456)
14. Verriest G (1963) Further studies on acquired deficiency of color discrimination. J Opt Soc Am 53:185-193.
15. Ladewig M, Kraus H, Foerster MH, Kellner U (2003) Cone dysfunction in patiens with late-onset cone dystrophy and age-related macular degeneration. Arch Ophthalmol 121:1557-1561. (Pubitemid 37392359)
16. Anastai M, Brai M, Lauricella M, Geracitano R (1993) Methodological aspects of the application of the Naka- Rushton equation to clinical electroretinogram. Ophthalmic Res 25:145-156. (Pubitemid 23197315)
17. Hébert M, Lachapelle P, Dumont M (1996) Reproducibility of electroretinogramms with DTL electrodes. Doc Ophthalmol 91:333-342.
18. Walter P, Widder RA, Luke C, Koenigsfeld P, Brunner R (1999) Electrophysiological abnormalities in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 237(12):962-968. (Pubitemid 30021285)
19. Luke M, Warga M, Ziemssen F et al (2006) Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 90:1178-1182. (Pubitemid 44351153)
20. Shahar J, Avery RL, Heilweil G et al (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26:262-269. (Pubitemid 44318177)
21. Manzano RP, Peyman GA, Khan P, Kivilcim M (2006) Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26:257-261; (Pubitemid 44318176)
22. Graefe's Arch Clin Exp Ophthalmol 237:962-968.
23. Feiner L, Barr EE, Shui YB, Holekamp NM, Brantley MA Jr (2006) Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 26:882-888. (Pubitemid 44547440)
24. Maturi RK, Bleau LA, Wilson DL (2006) Electrophysiologic findings after bevacizumab (Avastin) treatment. Retina 26:270-274. (Pubitemid 44318178)
25. Moschos MM, Brouzas D, Apostolopoulos M, Koutsandrea C, Loukianou E, Moschos M (2007) Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study: multifocal-ERG after use of bevacizumab in ARMD. Doc Ophthalmol 114:37-44. (Pubitemid 46206514)
26. Feigl B, Brown B, Lovie-Kitchin J, Swann P (2003) Conemediated multifocal electroretinogramm in early age-related maculopathy and its relationships with subjective macular function tests. Curr Eye Res 29:327-336. (Pubitemid 40095018)
27. Phipps JA, Guymer RH, Vingrys AJ (2003) Loss of cone function in age-related maculopathy. Invest Ophthalmol Vis Sci 44:2277-2283. (Pubitemid 36520327)
28. Arden GB, Wolf JE (2004) Colour vision testing as an aid to diagnosis and management of age related maculopathy. Br J Ophthalmol 88:1180-1185. (Pubitemid 39141380)
29. Scholl HPN, Zrenner E (2000) Electrophysiology in the investigation of acquired retinal disorders. Surv Ophthalmol 45:29-47. (Pubitemid 30628687)
30. Spitzer MS, Wallenfels-Thilo B, Sierra A et al (2006) Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol 90:1316-1321. (Pubitemid 44621499)
31. Luthra S, Narayanan R, Marques LE et al (2006) Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 26:512-518. (Pubitemid 44620391)
32. Heiduschka P, Fietz H, Hofmeister S et al (2007) Penetration of bevacizumab through the retina after intravitreal injection in monkey. Invest Opht Vis Res 48:2814-2823. (Pubitemid 351261238)
33. Gora-Kupilas K, Josko J (2005) The neuroprotective function of vascular endothelial growth factor (VEGF). Folia Neuropathol 43:31-39. (Pubitemid 40533190)